SCRS announced a two-year collaboration with Clinical Ink
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Clinical Ink, the pioneering provider of eSource solutions for clinical trials. Clinical Ink will participate as a Global Impact Partner (GIP) and align with other sponsors, CROs and service providers who share an ongoing commitment to research site success.
“Clinical Ink’s relationship with SCRS illustrates their commitment to strengthening site partnerships and accelerating collaboration amongst industry stakeholders,” comments Christine Pierre, SCRS President. “Working together with this leading organization is a significant strategic development for SCRS, and will add considerable momentum to our Global Impact Partnership program. SCRS is proud to welcome Clinical Ink to our community.”
“This partnership reinforces our commitment to sites and dedication to making clinical research easier for sites, sponsors, subjects and regulators,” said Ed Seguine, CEO, Clinical Ink. “Clinical Ink was co-founded by a clinical investigator who understood the challenges of clinical research from 20+ years of experience. Through new collaborations as an SCRS GIP, we look forward to gaining insights that will help guide the continued evolution of SureSource as a primary tool for sites.”
As a Global Impact Partner (GIP), Clinical Ink will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.